HealthcareServices

Infectious Disease Clinical Trials Market Performance Outlook 2026–2030: Revenue to Hit $21.24 Billion at 7.1% CAGR

February 25, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the infectious disease clinical trials market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Infectious Disease Clinical Trials Market’s size between 2026 and 2030?

The market size for infectious disease clinical trials has experienced substantial growth in recent years. It is anticipated to expand from $15.1 billion in 2025 to $16.13 billion in 2026, registering a compound annual growth rate (CAGR) of 6.8%. This historical growth can be attributed to several factors, including the expanding global burden of infectious diseases, increased financial support for vaccine development, the expansion of multinational clinical trial networks, the integration of digital trial management systems, and a rise in public health research endeavors.

The infectious disease clinical trials market size is projected to experience robust growth in the forthcoming years, reaching $21.25 billion by 2030 with a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period can be attributed to several factors including increasing investments in pandemic preparedness, the rising use of AI-assisted patient recruitment, the expansion of global trial decentralization, a growing focus on accelerated regulatory approvals, and the increasing integration of digital biomarkers. Major trends anticipated in the forecast period include the increasing adoption of data-driven trial design, a rising use of decentralized clinical trial models, the growing integration of real-world evidence, the expansion of adaptive trial methodologies, and an enhanced focus on rapid pathogen response.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29097&type=smp

Which Drivers Are Shaping Strategic Decisions In The Infectious Disease Clinical Trials Market?

The expansion of healthcare infrastructure is anticipated to fuel the growth of the infectious disease clinical trials market. This infrastructure includes physical facilities, medical equipment, technologies, and a trained workforce essential for delivering healthcare services and enabling effective disease prevention, diagnosis, and treatment. Its development is increasing due to the rising demand for advanced medical services, the growing burden of emerging and complex diseases, and the need for well-equipped facilities and skilled professionals to provide timely diagnosis, treatment, and preventive care. This infrastructure directly supports clinical trial capacity by offering advanced medical facilities, specialized equipment, and enhanced research capabilities crucial for conducting comprehensive infectious disease studies. For instance, in January 2025, according to the American Hospital Association, the total number of hospitals in the United States is projected to reach 6,093 by 2025, reflecting a modest growth in healthcare facilities nationwide. Therefore, the rising healthcare infrastructure is a key driver for the growth of the infectious disease clinical trials market.

What Segment Classifications Make Up The Infectious Disease Clinical Trials Market?

The infectious disease clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications

3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies

4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies

5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users

Subsegments:

1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies

2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies

3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies

4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies

What Upcoming Trends Are Likely To Define The Future Path Of The Infectious Disease Clinical Trials Market?

Major companies active in the infectious disease clinical trials market are concentrating on developing advanced research initiatives, including phase 3 trials of antibiotic candidates, to aid in uncovering rare side effects and confirming the most effective dosing. A phase 3 trial involving antibiotic candidates is a late-stage investigation that assesses the medication in a large group of patients to evaluate its safety, effectiveness, and how it compares to current therapies before it can receive approval for use. For example, in May 2025, Roche, a pharmaceutical firm based in Switzerland, initiated a Phase 3 clinical trial for zosurabalpin, a new tethered macrocyclic peptide antibiotic specifically engineered to fight CRAB, a significant cause of severe hospital infections worldwide. The distinctive characteristic of Zosurabalpin lies in its novel mechanism of action, which obstructs the transport of lipopolysaccharide crucial for building the bacterial outer membrane, with no resistance noted thus far. The international trial will involve around 400 patients to evaluate its safety and effectiveness in comparison to standard treatments. Early studies have indicated powerful activity against multidrug-resistant bacteria, excellent tolerability, and promising pharmacokinetic properties, thereby positioning Zosurabalpin as a potentially groundbreaking solution for tackling the urgent challenge of antibiotic resistance.

Which Key Market Players Are Investing In Expansion And Innovation Within The Infectious Disease Clinical Trials Market?

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Which Regions Are Projected To Dominate The Infectious Disease Clinical Trials Market In The Coming Years?

North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Infectious Disease Clinical Trials Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=29097&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Clinical Trials Market 2026, By The Business Research Company

Clinical Trial Management Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-trial-management-systems-global-market-report

Virtual Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report

Clinical Trial Supplies Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-trial-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795